Renalase (RNLS) is a protein playing different roles inside and outside cells. A 20-mer synthetic peptide corresponding to the human RNLS amino acid sequence 220-239 (RP220) exhibits a number of pharmacologically attractive activities in vitro and in vivo and can bind to many renal intracellular proteins. The RP220 sequence contains several cleavage sites for extracellular and circulating proteases. Here, we investigated the interaction of model proteins with the renalase peptide RP220 and a synthetic peptide corresponding to the amino acid sequence of RNLS 224-232, named RP224-232. We also performed affinity-based proteomic profiling of normotensive rat kidney samples with these peptides as affinity ligands. The obtained results indicate that both peptides exhibit almost the same affinity for model proteins (pyruvate kinase and lactate dehydrogenase), and the kidney proteomic profiles differ slightly. At the same time, the relative content of a number of kidney proteins bound to the RP224-232 peptide was even higher than in the case of using RP220. This suggests that proteolytic processing of RP220 does not inactivate this peptide; moreover, it could contribute to the formation of shorter peptides with additional pharmacological activities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.18097/PBMCR1559 | DOI Listing |
Protein-energy wasting (PEW) facilitates major adverse clinical outcomes in chronic renal failure (CRF), with current therapies not suitable for all patients. Faecalibacterium prausnitzii (F. prausnitzii) can alleviate chronic kidney disease, with unclear effects and mechanisms on CRF with PEW.
View Article and Find Full Text PDFInt J Nanomedicine
March 2025
Department of Vascular Surgery, the second Xiangya Hospital, Central South University, Changsha, 410011, People's Republic of China.
Introduction: Arteriovenous graft (AVG) is an important option for establishing hemodialysis access in patients with end-stage chronic kidney disease (CKD). Decellularized tissue-engineered vascular graft (dTEVG), due to its excellent biocompatibility and regenerative potential, holds promise for use in AVG; however, poor remodeling remains a challenge. Quercetin (Qu) can effectively regulate macrophage polarization and promote tissue remodeling and regeneration, yet its low bioavailability limits its clinical application.
View Article and Find Full Text PDFUnlabelled: Sparsentan, a dual endothelin receptor A inhibitor and angiotensin blocker, reduced proteinuria in patients with focal segmental glomerulosclerosis (FSGS) in Phase II and Phase III studies. However, the estimated glomerular filtration rate (eGFR) endpoint was not achieved, partially attributed to disease heterogeneity among participants. Sparsentan reversed the molecular fingerprint in kidneys of an adriamycin-challenged rat model of chronic kidney disease, consistent with the phenotypic data.
View Article and Find Full Text PDFJ Biochem Mol Toxicol
March 2025
Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Sunitinib (SUN) is a chemotherapeutic agent showing renal toxicity that limits its clinical applications. The present research aimed to clarify the potential ameliorative effects of secukinumab (SEC) and dapagliflozin (DAPA) against SUN-induced renal toxicity and the underpinning molecular mechanisms. For this purpose, adult Wistar albino rats were received SUN (25 mg/kg 3 times/week, po) and co-treated with SEC (3 mg/kg/every 2 weeks, subcutaneously) or DAPA (10 mg/kg/day, po) for 4 weeks and compared with age-matched control group (CON).
View Article and Find Full Text PDFSci Rep
March 2025
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alazarita 21521, Alexandria, Egypt.
Preeclampsia (PE) and peripartum sepsis are two complications of pregnancy and are often associated with disturbed renal function due possibly to dysregulated renin angiotensin system. Here we evaluated hemodynamic and renal consequences of separate and combined PE and sepsis insults in weaning mothers and tested whether this interaction is influenced by prenatally-administered losartan (AT1-receptor blocker) or pioglitazone (PPARγ agonist). The PE-rises in blood pressure and proteinuria induced by gestational nitric oxide synthase inhibition (L-NAME, 50 mg/kg/day for 7 days) were attenuated after simultaneous treatment with losartan or pioglitazone.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!